A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis group B outer membrane protein produces protective antibodies against gram-negative bacteremia

被引:48
作者
Bhattacharjee, AK
Opal, SM
Taylor, R
Naso, R
Semenuk, M
Zollinger, WD
Moran, EE
Young, L
Hammack, C
Sadoff, JC
Cross, AS
机构
[1] BROWN UNIV,SCH MED,PROVIDENCE,RI 02912
[2] UNIVAX BIOL INC,ROCKVILLE,MD
关键词
D O I
10.1093/infdis/173.5.1157
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Earlier studies showed that purified IgG from sera of rabbits immunized with a boiled Escherichia coli J5 (Re chemotype) whole cell vaccine protected neutropenic rats against gram-negative bacterial sepsis, In the present study, de-O-acylated J5 lipopolysaccharide (J5 DLPS) as a noncovalent complex with Neisseria meningitidis group B outer membrane protein (GBOMP) elicited anti-J5 LPS antibodies in rabbits, IgG prepared from immune rabbit sera protected neutropenic rats against lethal challenge with Pseudomonas aeruginosa 12:4:4 (Fisher Devlin immunotype 6), Sixteen of 26 rats treated with the postimmune serum IgG were protected compared with none of 20 rats treated with the control rabbit serum IgG (P <.001), In vitro binding studies showed binding of anti-J5 IgG to several gram-negative bacteria, These results indicate that a subunit vaccine made of J5 DLPS as a noncovalent complex with GBOMP may protect against gram-negative bacteremia.
引用
收藏
页码:1157 / 1163
页数:7
相关论文
共 35 条
[1]  
Ashcroft M T, 1967, Lancet, V2, P1056
[2]   AFFINITY-PURIFIED ESCHERICHIA-COLI J5 LIPOPOLYSACCHARIDE-SPECIFIC IGG PROTECTS NEUTROPENIC RATS AGAINST GRAM-NEGATIVE BACTERIAL SEPSIS [J].
BHATTACHARJEE, AK ;
OPAL, SM ;
PALARDY, JE ;
DRABICK, JJ ;
COLLINS, H ;
TAYLOR, R ;
COTTON, A ;
CROSS, AS .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (03) :622-629
[3]   ANTIBODIES TO MENINGOCOCCAL H.8(LIP) ANTIGEN FAIL TO SHOW BACTERICIDAL ACTIVITY [J].
BHATTACHARJEE, AK ;
MORAN, EE ;
ZOLLINGER, WD .
CANADIAN JOURNAL OF MICROBIOLOGY, 1990, 36 (02) :117-122
[4]  
BHATTACHARJEE AK, 1975, J BIOL CHEM, V250, P1926
[5]   A CONTROLLED CLINICAL-TRIAL OF HIGH-DOSE METHYLPREDNISOLONE IN THE TREATMENT OF SEVERE SEPSIS AND SEPTIC SHOCK [J].
BONE, RC ;
FISHER, CJ ;
CLEMMER, TP ;
SLOTMAN, GJ ;
METZ, CA ;
BALK, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (11) :653-658
[6]   IMMUNIZATION AGAINST NOSOCOMIAL INFECTION [J].
BRAUDE, AI ;
ZIEGLER, EJ ;
MCCUTCHAN, JA ;
DOUGLAS, H .
AMERICAN JOURNAL OF MEDICINE, 1981, 70 (02) :463-466
[7]  
BRAUDE AI, 1972, J IMMUNOL, V108, P505
[8]  
CHEDID L, 1968, J IMMUNOL, V100, P292
[9]   ORAL CIPROFLOXACIN AND A MONOCLONAL-ANTIBODY TO LIPOPOLYSACCHARIDE PROTECT LEUKOPENIC RATS FROM LETHAL INFECTION WITH PSEUDOMONAS-AERUGINOSA [J].
COLLINS, HH ;
CROSS, AS ;
DOBEK, A ;
OPAL, SM ;
MCCLAIN, JB ;
SADOFF, JC .
JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (06) :1073-1082
[10]   EVALUATION OF IMMUNOTHERAPEUTIC APPROACHES FOR THE POTENTIAL TREATMENT OF INFECTIONS CAUSED BY K1-POSITIVE ESCHERICHIA-COLI [J].
CROSS, AS ;
ZOLLINGER, W ;
MANDRELL, R ;
GEMSKI, P ;
SADOFF, J .
JOURNAL OF INFECTIOUS DISEASES, 1983, 147 (01) :68-76